COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN

被引：3
|
作者：
Jacob, J. [1 ]
Henriksson, M. [1 ]
Brattstrom, D. [1 ]
机构：
[1] AstraZeneca Nord MC, Sodertalje, Sweden
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71995-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A270 / A270
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [2] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [4] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [5] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Tardu, J.
    Millier, A.
    Insinga, R.
    Rai, A.
    Levy-Bachelot, L.
    Levy, P.
    VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [6] Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
    Zhang, Longfeng
    Li, Na
    Liu, Maobai
    Zheng, Bin
    Wu, Zhijuan
    Cai, Hongfu
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4263 - 4270
  • [7] Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective
    Lian, Dai
    Yang, Yi
    Gan, Yuling
    Xiao, Dunming
    Xiang, Yuliang
    Jiang, Shan
    Gu, Yuanyuan
    Chen, Yingyao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [8] Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer
    Narita, Yusuke
    Matsushima, Yukiko
    Shiroiwa, Takeru
    Chiba, Koji
    Nakanishi, Yoichi
    Kurokawa, Tatsuo
    Urushihara, Hisashi
    LUNG CANCER, 2015, 90 (01) : 71 - 77
  • [9] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [10] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345